Case Report

You have free access to this content

Osteonecrosis of the jaws associated with the use of yearly zoledronic acid: Report of 2 cases

  1. Jang-Jaer Lee DDS, MS1,2,
  2. Shih-Jung Cheng DDS, MS1,2,
  3. Yi-Ping Wang DDS, MS1,2,
  4. Jiiang-Huei Jeng DDS, PhD1,3,
  5. Chun-Pin Chiang DDS, PhD1,3,
  6. Sang-Heng Kok DDS, PhD1,2,*

Article first published online: 26 APR 2011

DOI: 10.1002/hed.21758

Issue

Head & Neck

Head & Neck

Volume 35, Issue 1, pages E6–E10, January 2013

Additional Information

How to Cite

Lee, J.-J., Cheng, S.-J., Wang, Y.-P., Jeng, J.-H., Chiang, C.-P. and Kok, S.-H. (2013), Osteonecrosis of the jaws associated with the use of yearly zoledronic acid: Report of 2 cases. Head Neck, 35: E6–E10. doi: 10.1002/hed.21758

Author Information

  1. 1

    Department of Dentistry, National Taiwan University Hospital, Taipei, Taiwan

  2. 2

    Department of Dentistry, School of Dentistry, College of Medicine, National Taiwan University, Taipei, Taiwan

  3. 3

    Graduate Institute of Clinical Dentistry, School of Dentistry, College of Medicine, National Taiwan University, Taipei, Taiwan

*Department of Dentistry, National Taiwan University Hospital, Taipei, Taiwan

Publication History

  1. Issue published online: 15 DEC 2012
  2. Article first published online: 26 APR 2011
  3. Manuscript Accepted: 24 JAN 2011

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (315K)

REFERENCES

  • 1
    American College of Obstetricians and Gynecologists, Women's Health Care Physicians. Osteoporosis ACOG practice bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 50, January 2003. Obset Gynecol 2004; 103: 203–216.
  • 2
    Boccuzzi SJ, Folz SH, Omar MA, Kahler KH. Assessment of adherence and persistence with daily and weekly dosing regimens of oral bisphosphonates. Osteoporosis Int 2005; 16 ( Suppl 4): S35–S36.
  • 3
    Lo JC, Pressman AR, Omar MA, et al. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporosis Int 2006; 17: 922–928.
  • 4
    Penning-van Beest FJ, Erkens JA, Olson M, et al. Determinants of noncompliance with bisphosphonates in women with postmenopausal osteoporosis. Curr Med Res Opin 2008; 24: 1337–1344.
  • 5
    Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809–1822.
  • 6
    Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. A review of the literature on osteonecrosis of the jaw in patient with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 2007; 29: 1548–1558.
  • 7
    Rizzoli R, Burlet N, Cahall D, et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 2008; 42: 841–847.
  • 8
    Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mebrotra B. American Association of Oral and Maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaws: 2009 update. J Oral Maxillofac Surg 2009; 67: 2–12.
  • 9
    Marx RE, Cillo JE, Ulloa JJ. Oral bisphosphonates induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007; 65: 2397–2410.
  • 10
    American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007; 65: 369–376.
  • 11
    Grbic JT, Landesberg R, Lin SQ. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc 2008; 139: 32–40.
  • 12
    Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115–1117.
  • 13
    Migliorati CA. Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol 2003; 21: 4253–4254.
  • 14
    Migliorati CA. Article analysis and evaluation on “Low incidence of osteonecrosis of the jaw in postmenopausal women with osteoporosis taking zoledronic acid once yearly.” J Evid Base Dent Pract 2009; 9: 13–15.
  • 15
    Woo SB, Hellstein JW, Kalmar JR. Narrative review: bisphosphonates and osteonecrosis of the jaws [corrected]. Ann Intern Med 2006; 144: 753–761.
  • 16
    Hoff AO, Toth BB, Altundag K, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008; 23: 826–836.
    Direct Link:
  • 17
    Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005; 23: 8580–8587.
  • 18
    Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006; 24: 945–952.
  • 19
    Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005; 63: 1567–1575.
  • 20
    Ruggiero S, Fralow J, Marx RE, et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2006; 2: 7–14.
  • 21
    Kunchur R, Need A, Hughes T, et al. Clinical investigation of C terminal cross linking telopeptide test in the prevention and management of bisphosphonate associated osteonecrosis of the jaws. J Oral Maxillofac Surg 2009; 67: 1167–1173.
  • 22
    Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346: 653–661.
  • 23
    McClung M, Miller P, Recknor C, Mesenbrink P, Bucci-Rechtweg C, Benhamou CL. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. Obstet Gynecol 2009; 114: 999–1007.
View Full Article (HTML) Get PDF (315K)